4th Sep 2014 08:46
LONDON (Alliance News) - Cyprotex PLC Thursday said it has been selected as a testing facility in the Comprehensive in vitro Proarrythmia Assay initiative which aims to devise new approaches for cardiac safety testing.
"Cyprotex is actively involved in the CiPA paradigm and is a leader in the field of in vitro cardiac safety testing, helping to determine future effective strategies for drug development," Chief Executive Anthony Baxter said in a statement.
"We look forward to commencing testing as part of the CiPA initiative in October/November this year," he added.
Cyprotex shares were untraded Thursday morning. The stock last traded at 52 pence per share.
By Anthony Tshibangu; [email protected]; @AnthonyAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
CRX.L